Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well E7389 works as second-line therapy in treating
patients with locally advanced, unresectable, or metastatic pancreatic cancer. Drugs used in
chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing.